In June 2018, BRCA genetic testing was covered as a companion diagnostic to PARP inhibitors for "BRCA mutation-positive and HER2-negative, inoperable or recurrent breast cancer with a history of cancer chemotherapy". Here, ERBB2 is linked to breast carcinoma.